229 related articles for article (PubMed ID: 32856727)
1. Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly-ADP-ribose polymerase inhibitors: A single-center experience.
Todisco E; Gigli F; Mantiero M; Sammassimo S; Pastano R; Ronchini C; Parma G; Lapresa MT; Iori AP; Bertolini F; Corsini C; Gregato G; Poletti C; Colombo N; Tarella C
Int J Cancer; 2021 Jan; 148(1):170-177. PubMed ID: 32856727
[TBL] [Abstract][Full Text] [Related]
2. Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes.
Todisco E; Gigli F; Ronchini C; Amato V; Sammassimo S; Pastano R; Parma G; Lapresa MT; Bertolini F; Corsini C; Gregato G; Poletti C; Pelicci PG; Alcalay M; Colombo N; Tarella C
Int J Cancer; 2022 Nov; 151(10):1791-1803. PubMed ID: 35695283
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: a cross-sectional study.
Cerda VR; Lu D; Scott M; Kim KH; Rimel BJ; Kamrava M
Int J Gynecol Cancer; 2022 Feb; 32(2):153-158. PubMed ID: 34911701
[TBL] [Abstract][Full Text] [Related]
4. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
5. Response to Chemotherapy and Clinical Outcome of Patients With Recurrent Epithelial Ovarian Cancer After PARP Inhibitor Maintenance Treatment: A Multicenter Retrospective Italian Study.
Gadducci A; Cosio S; Landoni F; Lissoni AA; Zola P; Laudani ME; Ardizzoia A; Gambino A; Sartori E
Anticancer Res; 2022 Apr; 42(4):2017-2022. PubMed ID: 35347023
[TBL] [Abstract][Full Text] [Related]
6. Epithelial ovarian cancer and brain metastases: might the
Sassu CM; Marchetti C; Russo G; Minucci A; Boccia SM; Benato A; Nero C; Piermattei A; Mattogno PP; Giannarelli D; Ferrandina G; Olivi A; Fagotti A; Scambia G
Int J Gynecol Cancer; 2024 Jan; 34(1):88-98. PubMed ID: 38805344
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for the failure of first-line PARP inhibitor maintenance therapy in patients with advanced ovarian cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA-3004).
Kim NK; Kim Y; Kim HS; Park SJ; Hwang DW; Lee SJ; Yoo JG; Chang SJ; Son JH; Kong TW; Kim J; Shim SH; Lee AJ; Suh DH; Lee YY
Cancer Med; 2023 Oct; 12(19):19449-19459. PubMed ID: 37768030
[TBL] [Abstract][Full Text] [Related]
8. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review.
Gupta S; Nag S; Aggarwal S; Rauthan A; Warrier N
J Ovarian Res; 2019 Nov; 12(1):103. PubMed ID: 31685032
[TBL] [Abstract][Full Text] [Related]
9. PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations.
Vanacker H; Harter P; Labidi-Galy SI; Banerjee S; Oaknin A; Lorusso D; Ray-Coquard I
Cancer Treat Rev; 2021 Sep; 99():102255. PubMed ID: 34332292
[TBL] [Abstract][Full Text] [Related]
10. Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
Vanacker H; Romeo C; Ray-Coquard I
Curr Opin Oncol; 2019 Sep; 31(5):394-403. PubMed ID: 31335830
[TBL] [Abstract][Full Text] [Related]
11. Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.
Washington C; Gunderson CC; Moore KN
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):4-11. PubMed ID: 30451713
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
Suh YJ; Lee B; Kim K; Jeong Y; Choi HY; Hwang SO; Kim YB
BMC Cancer; 2022 Mar; 22(1):346. PubMed ID: 35354431
[TBL] [Abstract][Full Text] [Related]
13. PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
Gauduchon T; Kfoury M; Lorusso D; Floquet A; Ventriglia J; Salaun H; Moubarak M; Rivoirard R; Polastro L; Favier L; You B; Berton D; de la Motte Rouge T; Mansi L; Abdeddaim C; Prulhiere K; Lancry Lecomte L; Provansal M; Dalban C; Ray-Coquard I
Gynecol Oncol; 2023 Jun; 173():98-105. PubMed ID: 37105063
[TBL] [Abstract][Full Text] [Related]
14. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
[TBL] [Abstract][Full Text] [Related]
15. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Tew WP; Lacchetti C; Ellis A; Maxian K; Banerjee S; Bookman M; Jones MB; Lee JM; Lheureux S; Liu JF; Moore KN; Muller C; Rodriguez P; Walsh C; Westin SN; Kohn EC
J Clin Oncol; 2020 Oct; 38(30):3468-3493. PubMed ID: 32790492
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
Rose PG; Yao M; Chambers LM; Mahdi H; DeBernardo R; Michener CM; AlHilli M; Ricci S; Vargas R
Anticancer Drugs; 2021 Nov; 32(10):1086-1092. PubMed ID: 34520432
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era-Is it time for a new paradigm shift? A systematic review and meta-analysis.
Peters ITA; Marchetti C; De Palma A; Giannarelli D; Carcagnì A; Scambia G; Fagotti A
Eur J Cancer; 2023 Jul; 187():77-86. PubMed ID: 37130463
[TBL] [Abstract][Full Text] [Related]
18. Poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer: lessons learned and future directions.
Caruso G; Tomao F; Parma G; Lapresa M; Multinu F; Palaia I; Aletti G; Colombo N
Int J Gynecol Cancer; 2023 Apr; 33(4):431-443. PubMed ID: 36928097
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of poly (ADP-ribose) polymerase inhibitors therapy for
Zhang M; Yu X; Wang J; Li Y; Cao L
J Cancer Res Ther; 2021 Dec; 17(7):1672-1678. PubMed ID: 35381738
[TBL] [Abstract][Full Text] [Related]
20. Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Marmouset V; Decroocq J; Garciaz S; Etienne G; Belhabri A; Bertoli S; Gastaud L; Simand C; Chantepie S; Uzunov M; Genthon A; Berthon C; Chiche E; Dumas PY; Vargaftig J; Salmeron G; Lemasle E; Tavernier E; Delage J; Loirat M; Morineau N; Blanc-Durand F; Pautier P; Vergé V; Auger N; Thomas M; Stefani L; Lepelley M; Boyer T; Thepot S; Gourin MP; Bourquard P; Duchmann M; Morice PM; Michallet M; Adès L; Fenaux P; Récher C; Dombret H; Pagès A; Marzac C; Leary A; Micol JB;
Clin Cancer Res; 2022 Dec; 28(23):5211-5220. PubMed ID: 36201165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
